Visit: http://sobp.societyconference.com



Click on the "Submissions" card and then clicking "login" will open the below popup window.



l	Enter your log in information	
a	User ID / E-mail Password	RG
	Remember my Login ID on this computer	
l	or	
l	Not a current user? Create a New User Account	
l	Forgot your password? Reset Password	
l	Change your Password	
l	This site is best viewed in latest versions of Chrome, Firefox, Safari and Microsoft Edge.	

Log in to your SOBP member account. If you do not know your password, please click "Forgot your Password? Reset Password" and a new password will be emailed.

Select Start a New Scientific Submission



These are your current submissions. You can access the submission by clicking the title. If you were added to a presentation by someone else, that submission would appear here.

Select the "Submission Type"	Submission Type
	Oral Presentation/Poster Symposia

For Symposia Chair Instructions please <u>click here</u> For Symposia Presenter Instructions please <u>click here</u> For Symposia Guidelines <u>click here</u> For Oral Presentation/Poster Instructions please <u>click here</u> For Oral Presentation/Poster Guidelines <u>click here</u>

Symposia Chair Instructions

	Save and Continue > Finalize Submission
io	n Type
a	
	Symposia Title *
	The title must be brief and clearly indicate the nature of the proposal.
	Test
	Apply 'Title Case' Formatting 196 of 200 characters remaining
	Research Area/Method *
	Please select a research area/method that is most applicable to your proposed session.
	Affective Neuroscience 🔹
	Psychiatric Conditions *
	Please select a secondary category psychiatric condition that is most applicable to your proposed session.
	Neurodegenerative Disorders -
	Research Type *
	Please select all options that best represents your research.
	Clinical
	Preclinical (including in silico)
	Animal

purposes. Please review the title after correction.

Select the <u>categories</u> that best describes your submission.

Symposia Chair Instructions



Search for a user by typing a full name or email. Please thoroughly search for a participant in the system before creating an account.

> These icons can be used to check the status of your participants. You can also click he mail icon to send an individual email.

Symposia Chair Instructions

### Complete the overall submission information.

General Participants Submission Disclosures	
1 Symposium Synopsis • Provide a clear, succinct synopsis of your proposed symposium (250 words or less). Describe the subject,	5 Video Permission •
highlighting the questions, scientific issues, innovations, and research to be addressed. DO NOT reference individual speakers in the synopsis.	The Society of Biological Psychiatry ("SOBP") may make a video recording of your presentation d 2025 SOBP Annual Meeting. In consideration of the decision by the SOBP to include the video rec your presentation during the 2025 SOBP Annual Meeting in its historical archives, and to make copic video recording available for educational purposes only (including posting on the SOBP web sufficiency and receipt of such consideration are hereby acknowledged, you agree as follows:
2 Diversity in Participants • Symposium participants should include scientists and/or clinicians who are diverse in gender, individuals from underrepresented backgrounds or underrepresented groups in science, technology, etc. In addition, symposis should attempt to include individuals who are at an early career stage. Please briefly describe how	1. You grant to SOBP the right to use and portray your name, likeness, voice, personality, identification, presentation and participation in the 2025 SOBP Annual Meeting. (All rights are hreferred to as the "Granted Rights.") You agree that the Granted Rights may be used for educational in any manner and by any means, with modifications as SOBP, its successors and assigns, determ sole discretion. You acknowledge that you are to receive no payment with respect to any matter rehrein. Any or all of the Granted Rights shall be freely assignable by SOBP.
the composition of your symposium addresses each of these ways to increase diversity among symposium participants.	2. You agree to release and discharge SOBP, its employees, agents, licensees, successors and assi any and all claims, demands or causes of action that you may now have or may hereafter have defamation, invasion of privacy or right of publicity, infringement of copyright or violation of any o arising out of or relating to any utilization of the Granted Rights or based upon any failure or om make use thereof.
	Nature of your participation in the 2025 SOBP Annual Meeting: CHAIR
3) Diversity in Scientific Topics * The SOBP strongly supports diversity in the scientific topics of symposia and seeks symposia that address	
important understudied factors (e.g., sex- and gender-based analyses, vulnerabilities and treatment gaps for minority populations, etc.) in psychiatric neuroscience. Please briefly describe how your symposium addresses the goal of content diversity.	6 Symposium Presentation Format Preference * Our plan is to hold a fully in-person conference with live, in-person symposia. Please confirm your present in-person if the symposium is accepted.
	<ul> <li>Our symposium will present in-person in Toronto.</li> </ul>
4 Attestation and Affirmation •	
<ul> <li>I have participated sufficiently in the work to take public responsibility for all or part of the content, AND have made substantive intellectual contributions to the submitted work in the form of conception and design, and/or acquisition of data, and/or analysis of data.</li> <li>Previous Presentations: The data in this submission may have been or may be presented elsewhere in abstract form, but it has not been published as an article on or before November 1, 2022.</li> <li>Third Party or Agency Submissions: This submission has not been made by an agency or third party. Any submissions by an agency or unrelated third party will not be considered.</li> <li>Scheduling: If accepted, I understand that this submission may be scheduled for presentation on any day of</li> </ul>	Next, select "Save and Continue" to move to your disclosure Save and Continue >
the conference (Thursday, April 27 - Saturday, April 29, 2023). • Registration: All member and non-member presenters are required to register for the meeting in order to present. • I attest that all information submitted is accurate. I Agree	Note: you will not be able to <u>finalize</u> <u>your submission</u> until all participants have submitted their abstracts & disclosur

Disclosures



\* You must populate all fields to complete the row.

#### Statement 1 \*

I will not accept payments or reimbursements from an ineligible company (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients) for my role in the planning and delivery of this CME activity. If I am approached by an ineligible company in this regard, I will immediately notify SOBP.

I Agree.

Statement 2 \*

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. If I am a presenter, my presentation will meet these standards, and if I'm a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards.

I Agree.

Statement 3 \*

olutoment o

Presentations that promote recommendations, treatment, or manners of practicing medicine that are not within the definition of CME or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients, are prohibited. Presentations devoted to advocacy of unscientific modalities of diagnosis or therapy are prohibited. If I am a presenter, my presentation will meet these standards, and if I'm a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards. Include any ineligible company that you've received funds from.

Be sure to agree to each statement.

#### Statement 4 •

All recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis. If I am a presenter, my presentation will meet these standards, and if I am a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards.

I Agree

#### Statement 5 •

Presentations must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the CME educational material or content that includes trade names should include trade names from several companies where available, not just trade names from a single company. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion will meet this standard.

I Agree.

#### Statement 6 \*

Educational materials that are a part of this activity, such as slides, abstracts, and handouts, cannot contain any advertising, trade names, or product-group messages, or ineligible company logos. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion will meet this standard.

I Agree

#### Statement 7 •

The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. If I am a presenter, my presentation will meet this standard, and if I'm a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet this standard.

I Agree

#### Statement 8 +

The content of the CME activity must not be influenced by any ineligible company. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard.

I Agree

#### Statement 9 +

If you are an employee or corporate board member of an ineligible company, we will review your disclosure and decide if further action is, or is not, necessary.

I agree

#### Employee Disclosure •

Are you an employee or owner of an ineligible company, or do you hold stock/equity in a privately held ineligible company?

Yes

O No

#### Disclosure Resolution •

	Yes	No
Is your company/employer/private stock producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients?	۲	0
Is your company/employer/private stock a provider of clinical services directly to patients?	0	۲
Is the content of the activity as a whole related in any way to products or business lines of your company/employer/private stock?	0	۲

14 Resume/CV •

Please upload a copy of your Resume/CV (.DOC/.PDF)



(15) Signature •

I certify that all my affiliations with or financial relationships (e.g., employment, consultancies, honoraria, equity ownership or stock options, grants, contracts, patents, received or pending, or royalites) with any organization or employ defined as an ineligible company are disclosed complexity here. For purposes of disclosure, financial involvement is defined as any income source having occurred within the last 24 months. In order to accredit the conference, we need to know if your relationship with your ineligible company in relation to the content of your presentation. Please answer these questions if you are employed, an owner or hold stock/equity in a privately held company.

Upload a pdf of your CV

Symposia Chair Instructions

### **Finalizing your submission**

Return to Dashboard	d Submit Symposia						
General 🥑	Participants	iion 🕜	Disclosures	<u>s</u>			
<ul> <li>As Chair, you are</li> <li>If your symposiu member speaker</li> <li>If you or your spear</li> </ul>	✓ Previous Satisfy a symposium win receive speaking in a symposium win receive responsible for communicating this policy m is accepted, you will receive instructio s. SOBP will then communicate registratic eakers are unsure about eligibility for finance and the spectrum of the spec	ve and Continu we a reduced y to any speak ns from sobp n instructions cial support, c	ers you invite. @sobp.org in m to all of your sp contact sobp@si	tid December aski beakers on or befo obp.org to verify p	ubmission ing you to tell re registration ast participati	SOBP how much opens. on.	money to provid
			Admin	Y		Y	Participant
Chair*	Christine Farwell cfarwell@parthenonmgmt.com	remove	$\checkmark$	Submitted In Progress		Submitted In Progress	
Presenter *	Tori Swinehart	remove			$\land$		
	tswinehart@parthenonmgmt.com	Ŷ		Submitted	Б	Submitted	
Presenter *	Megan Pich mpich@parthenonmgmt.com	remove ↑↓		Submitted	$\bigcirc$	Submitted	
Presenter *	Payton McClintock pmcclintock@parthenonmgmt.com	remove ↑↓		Submitted	ß	Submitted	
Presenter *	Christine Farwell cfarwell@parthenonmgmt.com	remove	<b>&gt;</b>	Submitted	67	Submitted	
	Add Participant						

When all presenters have completed their respective tasks the finalized submission button will change to yellow. Click this to submit your proposal for review.

Symposia Presenter Instructions

Go to your "Submissions Dashboard" and scroll down to the bottom of the page. Click on the title of the Symposia Submission to submit your individual abstract and disclosures.

	2025 SOBP	Annual Meeting	*All deadlines are 5	Apri	l 24 - 26, 2025	
		Start a New Scientific Submission	Submit Travel Fellowship Awards	Submit SOBP Awards	Submit Special Pro	bjects
		Click on abs	stract title below to update and s	ubmit individual and supporti	ng abstracts.	
	Status	My Submissions		Туре	Role	
	Not Started	Test		Poster	Presenter	delete

Symposia Presenter Instructions

### As a presenter, please complete the following fields.

_	Participants Submission <u>3</u> Dir	actosures 4			
	Previous     Save and Continue		Submit Abstract	250 of 250 overall words rer	maining
Ab	ostract Title •				
Th	e title must be brief and clearly indicate the nature of the abstract.				
•	Test	105-5000			
Tit	le Case' formatting has been applied. Please review and edit as needed	1. 196 of 200 (	characters remaining		
Sti	atistical Analysis +				
co	clusion of statistical analysis is required, including p and n value nsideration for selection.	s, for submission	s to receive full		
Ab	stracts that contain no information regarding sample size or statistical	tests will have a h	igh probability of		
be ou	ing rejected. Similarly, abstracts that report single case studies and/c tside the realm of Psychiatry will be likely to be rejected. Please see an e	r report data from xample of a succes	studies in areas sful abstract as a		
jer	nplate for the abstract submission process.				
	rnave read the adove and understand.				
Ba	ckground: •				
Ab	rief statement on the purpose of the study and the current state of res	earch in the field.			
Me	ethods: •				
Th	e study methods, or experimental approach, clearly but briefly defined.				
Re	sults: *				
A : to	summary of the results of the study, including sufficient details, numbe support those conclusions.	r of subjects, and r	elevant statistics		
Co	onclusions: •				
Co	onclusions: • statement about the significance of the work.			7	
C a	onclusions: • statement about the significance of the work.				
A	onclusions: • statement about the significance of the work.				
	onclusions: • statement about the significance of the work.				
F	onclusions: • statement about the significance of the work. unding Source •				
C A	onclusions: • statement about the significance of the work. unding Source • st any funding sources supporting this research (i.e., RO1XXXXX, na Infunded".	ames of foundatio	ns, etc.) or select		
	onclusions: • statement about the significance of the work. unding Source • st any funding sources supporting this research (i.e., R01XXXXX, no Infunded". ) Unfunded ) Funding Source	ames of foundatio	ns, etc.) or select		
	unding Source • statery funding source supporting this research (i.e., R01XXXXX, na Infunded".	ames of foundatio	ns, etc.) or select		
	onclusions: • statement about the significance of the work. unding Source • ist any funding sources supporting this research (i.e., R01XXXXX, na Jnfunded". ) Unfunded ) Funding Source eywords: •	ames of foundatio	ns, etc.) or select		
	onclusions: • statement about the significance of the work. unding Source • ist any funding sources supporting this research (i.e., R01XXXXX, no Infunded". ) Unfunded ) Funding Source eywords: • nter up to 5 keywords	ames of foundatio	ns, etc.) or select		
	onclusions: •	ames of foundatio	ns, etc.) or select		
	ionclusions: • istatement about the significance of the work.  unding Source • ist any funding sources supporting this research (i.e., R01XXXXX, na Jnfunded". ) Unfunded ) Funding Source ieywords: • nter up to 5 keywords Search for keywords to be added. If keyword is not found, then enter Calculate Search for keyword	ames of foundatio	ns, etc.) or select		
	ionclusions: • Istatement about the significance of the work.  unding Source • Ist any funding sources supporting this research (i.e., R01XXXXX, no Infunded".  ) Unfunded ) Funding Source Reywords: • Inter up to 5 keywords Search for keywords to be added. If keyword is not found, then enter Reywords Search for keyword Keywords	ames of foundatio	ns, etc.) or select		
	onclusions: • statement about the significance of the work. unding Source • ist any funding sources supporting this research (i.e., RO1XXXXX, na Infunded'. ) Unfunded ) Funding Source eywords: • nter up to 5 keywords Search for keywords to be added. If keyword is not found, then enter Rearch for keywords Search for keyword Keyword Keywords Du must enter at least 3 keywords	ames of foundatio	ns, etc.) or select		
	onclusions: • statement about the significance of the work.  unding Source • ist any funding sources supporting this research (i.e., RO1XXXXX, na Infunded". ) Unfunded ) Funding Source eywords: • nter up to 5 keywords Search for keywords to be added. If keyword is not found, then enter Caller Galler Everywords Everywo	ames of foundatio ar directly in the ta	ns, etc.) or select Ible below.	a	
	inclusions: • Istatement about the significance of the work.  Inding Source • Ist any funding sources supporting this research (i.e., R01XXXXX, no Infunded". Infunded Infunde	ames of foundatio ar directly in the ta the search box. low. Please use t	ns, etc.) or select able below.	a e	
	ionclusions: •	ames of foundatio er directly in the ta the search box. low. Please use to	ns, etc.) or select ble below.	a	
	ionclusions: •  Istatement about the significance of the work.  Infunding Source •  Ist any funding sources supporting this research (i.e., R01XXXXX, no  Infunded".  Unfunded	ames of foundatio ar directly in the ta the search box. low. Please use t nter directly in the	ns, etc.) or select tble below.	a e	
	onclusions: • statement about the significance of the work.  unding Source • ist any funding sources supporting this research (i.e., R01XXXXX, no Infunded". ) Unfunded ) Funding Source eywords: • nter up to 5 keywords Search for keywords to be added. If keyword is not found, then ente Q Search for keyword Keywords nuer at least 3 keywords nuer at least 3 keywords nuer at least 3 keywords euthors by using o-author in this database, you may type them into the grid be uthorship into the correct order. Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Q Search for co-authors to be added. If co-author is not found, then ente Search for co-authors to be added. If co-author is not found, t	ames of foundatio ar directly in the ta the search box. low. Please use to nter directly in the	ns, etc.) or select ble below.	a	
	tonclusions: •  tonclusions: •  tonclusions: •  tonclusions: •  tonclusions: •  tonclusions: •  tonding Source •  ist any funding sources supporting this research (i.e., R01XXXXX, no  Jufunded')  Unfunded  Definition Source  topwords: •  ther up to 5 keywords  Search for keywords to be added. If keyword is not found, then enter  Call Search for keyword  Keywords  ther all co-authors to be added. If co-author is not found, then enter  Call Call Search for co-authors to be added. If co-author is not found, then enter  Call Call Search for co-authors to be added. If co-author is not found, then enter  Call Call Search for co-authors to be added. If co-author is not found, then enter  Call Call Search for co-authors to be added. If co-author is not found, then enter  Call Call Search for co-authors to be added. If co-author is not found, then enter  Call Call Search for co-authors to be added. If co-author is not found, then enter  Call Call Search for co-authors to be added. If co-author is not found, then enter  Call Search for co-authors to be added. If co-author is not found, then enter  Call Search for co-authors to be added. If co-author is not found, then enter  Call Search for co-authors to be added. If co-author is not found, then enter  Call Search for co-authors to be added. If co-author is not found, then enter  Call Search for co-authors to be added. If co-authors is not found, then enter  Call Search for co-authors to be added. If co-authors is not found, then enter  Call Search for co-authors to be added. If co-authors is not found, then enter  Call Search for co-authors to be added. If co-authors is not found, then enter  Call Search for co-authors to be added. If co-authors is not found, then enter  Call Search for co-authors to be added. If co-authors is not found, then enter  Call Search for co-authors to be added. If co-author is not found, then enter  Call Search for co-authors to be added. If co-authors is not found, then enter  Call Search for co-authors to be added. If co-authors is not fou	ames of foundatio er directly in the ta the search box. low. Please use t nter directly in the	ns, etc.) or select ble below. If you cannot find the arrows to mov e table below. Affiliation • Parthenon Manage	a e	
C A C F LL C C K E C A C C C A C C C A C C C A C C C A C C C A C C C A C C C A C C C C A C	inclusions: •         istatement about the significance of the work.         unding Source •         ist any funding sources supporting this research (i.e., R01XXXXX, not infunded".         ) Unfunded         ) Funding Source         eywords: •         inter up to 5 keywords         Search for keywords to be added. If keyword is not found, then entropy         Q         Search for keywords         Search for keywords         Veywords         Inter all co-authors. You may search for any co-authors by using o-author in this database, you may type them into the grid bell uthorship into the correct order.         Search for co-authors to be added. If co-author is not found, then entropy to authors in the correct order.         Search for co-authors to be added. If co-author is not found, then entropy to authors in the correct order.         Search for co-authors to be added. If co-author is not found, then entropy to author in the correct order.         Search for co-authors to be added. If co-author is not found, then entropy to author is not found then entropy to a author is not found.         Q       Q         Search for co-authors to be added. If co-author is not found, then entropy to a author is not found.         Q       Q         Search for co-authors to be added. If co-author is not found, then entropy to a author is not found then entropy to a author is not found thentent authonent is a author is not found author is not f	ames of foundatio er directly in the ta the search box. low. Please use to nter directly in the	ns, etc.) or select tble below. If you cannot find the arrows to mov table below.	a e	
	Conclusions: •         A statement about the significance of the work.         Funding Source •         ist any funding sources supporting this research (i.e., R01XXXXX, no Unfunded".         O Unfunded         O Unfunded         Funding Source         Keywords: •         inter up to 5 keywords         Search for keywords to be added. If keyword is not found, then entre         Q         Search for keywords         Keywords         inter all co-authors. You may search for any co-authors by using on-author in this database, you may type them into the grid bel uthorship into the correct order.         Search for co-authors to be added. If co-author is not found, then entre         Q         Search for co-authors to be added. If co-author is not found, then entre         Q         Search for co-authors to be added. If co-author is not found, then entre         Q         Search for co-authors to be added. If co-author is not found, then entre         Q         Search for co-authors to be added. If co-author is not found, then entre         Q         Search for co-authors to be added. If co-author is not found, then entre         Q         Search for co-authors to be added. If co-author is not found, then entre         Q         Search for co-author <tr< td=""><td>ames of foundatio er directly in the ta the search box. low. Please use t nter directly in the</td><td>ns, etc.) or select ble below. If you cannot find the arrows to mov table below. Affiliation • Parthenon Manag</td><td>a e</td><td></td></tr<>	ames of foundatio er directly in the ta the search box. low. Please use t nter directly in the	ns, etc.) or select ble below. If you cannot find the arrows to mov table below. Affiliation • Parthenon Manag	a e	
	Conclusions: •   A statement about the significance of the work.     Funding Source •   ist any funding sources supporting this research (i.e., R01XXXXX, no Unfunded").   •) Unfunded   •) Funding Source   Reywords: •   inter up to 5 keywords   Search for keywords to be added. If keyword is not found, then enter a least 3 keywords   Search for keywords   Search for keywords   Search for co-authors. You may search for any co-authors by using to-author in this database, you may type them into the grid bel uthorship into the correct order.   Search for co-authors to be added. If co-author is not found, then enter at least 3 keywords   Search for co-authors to be added. If co-author is not found, then enter at least 3 keywords   Search for co-authors to be added. If co-author is not found, then enter at least 3 keywords   Search for co-authors to be added. If co-author is not found, then enter at least 3 keywords   Search for co-authors to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords to be added. If co-author is not found, then enter at least 1 keywords is not four at least 1 keywords is not four at least 1 keywords is not four at lea	ames of foundatio er directly in the ta the search box. low. Please use to nter directly in the	ns, etc.) or select ble below. If you cannot find the arrows to mov e table below. Affiliation • Parthenon Manag	a e gement Group	
	Sonclusions: •   A statement about the significance of the work.     Funding Source •   ist any funding sources supporting this research (i.e., R01XXXXX, no unfunded".   > Unfunded   > Funding Source   Reywords: •   inter up to 5 keywords   Search for keywords   Search for keywords   Search for keywords   Search for keywords   inter all co-authors. You may search for any co-authors by using on-outhor in this database, you may type them into the grid bell uthorship into the correct order.   Search for co-authors to be added. If co-author is not found, then end on-outhor in this database, you may type them into the grid bell uthorship into the correct order.   Search for co-authors to be added. If co-author is not found, then end on-outhor in this database, you may type them into the grid bell uthorship into the correct order.   Search for co-authors to be added. If co-author is not found, then end on-outhor in this database. You may type them into the grid bell uthorship into the correct order.   Search for co-authors to be added. If co-author is not found, then end on-outhor is not found, then end on-outhor is not found thend on-outhon is not f	ames of foundatio are directly in the ta the search box. low. Please use to nter directly in the	ns, etc.) or select ble below. If you cannot find the arrows to mov table below.	a e gement Group	

published by Elsevier. Confirm below that permission was requested and given for their names to be used in this abstract:

All co-authors are aware and approve the use of their names on this abstract, which, if accepted, will

- be presented and published.
- $\bigcirc\,$  All co-authors are aware but do not approve of the publication of this abstract

#### Alternate Presentation Type

If this Symposium is not accepted for presentation, there will be an opportunity to resubmit your work as an oral or poster presentation before the Oral/Poster abstract deadline.

#### SOBP Role Limit Policy •

(11)

(12)

 For symposium only, a speaker may participate in no more than two sessions regardless of their role in the session. Example: A speaker may be a chair and also a speaker in a single session and that counts as one session.

 If a speaker is on more than two accepted sessions for presentation, SOBP will notify the Chair to determine resolution.

. There are no speaker role limits for oral or poster presentations.

I acknowledge and agree.

#### Attestation and Affirmation •

I have participated sufficiently in the work to take public responsibility for all or part of the content, AND
have made substantive intellectual contributions to the submitted work in the form of conception and design,
and/or acquisition of data, and/or analysis of data.

 Previous Presentations: The data in this submission may have been or may be presented elsewhere in abstract form, but it has not been published as an article on or before November 1, 2024.

 Third Party or Agency Submissions: This submission has not been made by an agency or third party. Any submissions by an agency or unrelated third party will not be considered.

 Scheduling: If accepted, I understand that this submission may be scheduled for presentation on any day of the conference (Thursday, April 24 - Saturday, April 26, 2025).

Registration: All member and non-member presenters are required to register for the meeting in order to present.

· I attest that all information submitted is accurate.

I Agree



The Society of Biological Psychiatry ('SOBP') may make a video recording of your presentation during the 2025 SOBP Annual Meeting. In consideration of the decision by the SOBP to include the video recording of your presentation during the 2025 SOBP Annual Meeting in its historical archives, and to make copies of that video recording available for educational purposes only (including posting on the SOBP website), the sufficiency and receipt of such consideration are hereby acknowledged, you agree as follows:

1. You grant to SOBP the right to use and portray your name, likeness, voice, personality, personal identification, presentation and participation in the 2025 SOBP Annual Meeting. (All rights are hereinafter referred to as the "Granted Rights.") You agree that the Granted Rights may be used for educational purposes in any manner and by any means, with modifications as SOBP; its successors and assigns, determine in its sole discretion. You acknowledge that you are to receive no payment with respect to any matter referred to herein. Any or all of the Granted Rights shall be freely assignable by SOBP.

2. You agree to release and discharge SOBP, its employees, agents, licensees, successors and assigns from any and all claims, demands or causes of action that you may now have or may hereafter have for libel, defamation, invasion of privacy or right of publicity, infringement of copyright or violation of any other right arising out of or relating to any utilization of the Granted Rights or based upon any failure or omission to make use thereof.

Nature of your participation in the 2025 SOBP Annual Meeting: PRESENTER

O I have read and agree to the above terms and conditions.

Disclosures



\* You must populate all fields to complete the row.

#### Statement 1 \*

I will not accept payments or reimbursements from an ineligible company (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients) for my role in the planning and delivery of this CME activity. If I am approached by an ineligible company in this regard, I will immediately notify SOBP.

I Agree.

Statement 2 \*

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. If I am a presenter, my presentation will meet these standards, and if I'm a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards.

I Agree.

Statement 3 \*

olutoment o

Presentations that promote recommendations, treatment, or manners of practicing medicine that are not within the definition of CME or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients, are prohibited. Presentations devoted to advocacy of unscientific modalities of diagnosis or therapy are prohibited. If I am a presenter, my presentation will meet these standards, and if I'm a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards. Include any ineligible company that you've received funds from.

Be sure to agree to each statement.

#### Statement 4 •

All recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis. If I am a presenter, my presentation will meet these standards, and if I am a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards.

I Agree

#### Statement 5 •

Presentations must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the CME educational material or content that includes trade names should include trade names from several companies where available, not just trade names from a single company. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion will meet this standard.

I Agree.

#### Statement 6 \*

Educational materials that are a part of this activity, such as slides, abstracts, and handouts, cannot contain any advertising, trade names, or product-group messages, or ineligible company logos. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion will meet this standard.

I Agree

#### Statement 7 •

The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. If I am a presenter, my presentation will meet this standard, and if I'm a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet this standard.

I Agree

#### Statement 8 +

The content of the CME activity must not be influenced by any ineligible company. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard.

I Agree

#### Statement 9 +

If you are an employee or corporate board member of an ineligible company, we will review your disclosure and decide if further action is, or is not, necessary.

I agree

#### Employee Disclosure •

Are you an employee or owner of an ineligible company, or do you hold stock/equity in a privately held ineligible company?

Yes

O No

#### Disclosure Resolution •

	Yes	No
Is your company/employer/private stock producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients?	۲	0
Is your company/employer/private stock a provider of clinical services directly to patients?	0	۲
Is the content of the activity as a whole related in any way to products or business lines of your company/employer/private stock?	0	۲

14 Resume/CV •

Please upload a copy of your Resume/CV (.DOC/.PDF)



(15) Signature •

I certify that all my affiliations with or financial relationships (e.g., employment, consultancies, honoraria, equity ownership or stock options, grants, contracts, patents, received or pending, or royalites) with any organization or employ defined as an ineligible company are disclosed complexity here. For purposes of disclosure, financial involvement is defined as any income source having occurred within the last 24 months. In order to accredit the conference, we need to know if your relationship with your ineligible company in relation to the content of your presentation. Please answer these questions if you are employed, an owner or hold stock/equity in a privately held company.

Upload a pdf of your CV

Oral Presentation/Poster Instructions



After entering the title, the system will autocorrect to title case. This is for Abstract and Program book purposes. Please review the title after correction.

Select the <u>categories</u> that best describes your submission.

Oral Presentation/Poster Instructions

### Participants: The person submitting the abstract is the Oral/Poster Presenter. Co-authors are added on Step 3 - Submission.



Participants

The presenting author is listed below. The person presenting must enter the abstract under their personal account. Please list your co-authors in the Submission Step 3.

Abstract

Presenter \*

Christine Farwell remove cfarwell@parthenonmgmt.com

Admin Status

Submission

Not Started

Disclosure

Status

**Oral Presentation/Poster Submission Instructions** 

### Please complete the following fields.



Funding Sou					
	irce •				
List any fun Unfunded.	ding sources	supporting this research (	(i.e., RO1XXXXX, names of foun	dations) or select	
O Unfunded	1				
Funding \$	Source				
Funding Sou	irce: •				
List any fund	ing sources s	upporting this research such	as a funding agency or sponsor o	f this research. i.e.,	If your research was funded, please list
R01; NARSAD	); NSF; Other				funding sources.
Keywords: •					
Enter 3 to 5 k	eywords				
Search for l	evwords to l	he added. If keyword is not f	found then enter directly in the t	able below	
Generation	icynolds to l	0	iound, then enter directly in the t		
Search for ke	eyword	~			
Keywo	ords				
			7		
/ou must ent	er at least 3 k	eywords			
	autions. To	u may search for any co-au	thors by using the search box.	If you cannot find a	
co-author in authorship i books.	this databa nto the corr	u may search for any co-au ase, you may type them in rect order. This is the orde	othors by using the search box. No the grid below. Please use ar that will be printed in our pr	If you cannot find a the arrows to move rogram and abstract	
co-author in authorship i books. Search for o	this databa	u may search for any co-au ase, you may type them in rect order. This is the orde	thors by using the search box. to the grid below. Please use er that will be printed in our pr ot found, then enter directly in th	If you cannot find a the arrows to move rogram and abstract e table below.	
co-author in authorship i books. Search for o	n this databa nto the corr	u may search for any co-au ase, you may type them in ect order. This is the orde be added. If co-author is no	thors by using the search box. to the grid below. Please use er that will be printed in our pr ot found, then enter directly in th	If you cannot find a the arrows to move rogram and abstract e table below.	
co-author in authorship i books. Search for o Search for co	co-authors to p-authors to p-authors to	u may search for any co-au ise, you may type them in ect order. This is the orde be added. If co-author is no	rthors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th	If you cannot find a the arrows to move rogram and abstract e table below.	
co-author in authorship i books. Search for co Search for co Order	co-authors to co-authors to co-authors to Presenter	u may search for any co-au isse, you may type them in ect order. This is the orde be added. If co-author is no Q First Name •	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name •	If you cannot find a the arrows to move rogram and abstract e table below.	
so-author in nuthorship i nooks. Search for co Search for co Order	co-authors to co-authors to p-author Presenter	u may search for any co-au isse, you may type them in ect order. This is the orde be added. If co-author is no Q First Name • Christine	thors by using the search box. to the grid below. Please use rr that will be printed in our pr ot found, then enter directly in th Last Name -	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation • Parthenon Management Group	
co-author in authorship i books. Search for o Search for o Order	co-authors to co-authors to co-authors to Presenter	u may search for any co-au isse, you may type them in ect order. This is the orde be added. If co-author is no Q. First Name • Christine	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name • Farwell	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation • Parthenon Management Group	
co-author in authorship i books. Search for o Order 1	co-authors to o-authors to o-author the corr Presenter	u may search for any co-au se, you may type them in ect order. This is the orde be added. If co-author is no Q First Name • Christine ds to complete the row.	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name • Farwell	If you cannot find a the arrows to move rogram and abstract a table below. Affiliation - Parthenon Management Group	
co-author in authorship i books. Search for o Search for or Order 1 * You must pr Christine	this database nto the corr co-authors to pauthor Presenter C Farwell <sup>1</sup>	u may search for any co-au se, you may type them in ect order. This is the orde u be added. If co-author is no Q First Name • Christine ds to complete the row.	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name - Farwell	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation • Parthenon Management Group	
co-author in authorship is books. Search for of Order 1 * You must pr Christine	this database nto the corr co-authors to co-author Presenter C Farwell <sup>1</sup>	u may search for any co-au se, you may type them in ect order. This is the orde u be added. If co-author is no Q First Name • Christine ds to complete the row.	nthors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name - Farwell	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation - Parthenon Management Group	
co-author in authorship is books. Search for co Search for co Order 1 * You must po Christine <sup>1</sup> Parthenc	this database nto the corr co-authors to co-author Presenter Co- populate all fiel Farwell <sup>1</sup> on Managem	u may search for any co-au se, you may type them in rect order. This is the orde u be added. If co-author is no Q First Name • Christine ids to complete the row.	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name - Farwell	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation • Parthenon Management Group	
co-author in authorship i books. Search for or Order Search for or Order Christine Partheno	this database nto the corr co-authors to c-author Presenter Co-author Farwell <sup>1</sup> con Managem Co-Authors F	u may search for any co-au see, you may type them in ect order. This is the orde of be added. If co-author is no order First Name • Christine ds to complete the row. ent Group Permission •	nthors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name - Farwell	If you cannot find a the arrows to move rogram and abstract a table below. Affiliation - Parthenon Management Group	
search for co Search for co Order Christine Parthence Attestation ( All co-authori	this database nto the corr co-authors to co-author to co-author Presenter Co-author Farwell <sup>1</sup> to Managem Co-Authors F s on this abst	u may search for any co-au see, you may type them in rect order. This is the orde of the added. If co-author is no one of the added. If co-author is no one of the order of the order First Name • Christine dis to complete the row. ent Group Permission • ract must approve of the press	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name • Farwell entation of this abstract at the SOB	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation - Parthenon Management Group	
search for co Search for co Order Christine Parthence Attestation ( All co-authors angliseceptu	this database nto the corr co-authors to co-author Presenter Co-author Farwell <sup>1</sup> co-authors F Farwell <sup>1</sup> Co-Authors F s on this abst ed, its publice Elsevier, Com	I may search for any co-au se, you may type them in ect order. This is the orde a be added. If co-author is no a be added.	entation of this abstract at the SOE pierment to the Society's journal. Bis a requested and over for the society of the society of the Society's for the Society's journal. Bis as requested and over for the society's journal. Bis as requested and over for the society's journal. Bis	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation - Parthenon Management Group BP Annual Meeting ological Psychiatry, meet to be used in	Please confirm that your co-authors p
search for co Search for co Order Christine Parthence Attestation ( All co-authors and, li soberdat:	this database nto the corr co-authors to co-authors to populate all fiel Farwell <sup>1</sup> Co-Authors F s on this abst ed, its publicic Elsevier. Cont	Ir may search for any co-au see, you may type them in ect order. This is the orde of be added. If co-author is no of the added. If c	entation of this abstract at the SOE plement to the Society's journal. Bits as requested and given for their na	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation - Parthenon Management Group BP Annual Meeting ological Psychiatry, ames to be used in	Please confirm that your co-authors p approved of the presentation and pul
search for co Search for co Order Search for co Order Christine Parthenco Attestation ( All co-author and, if accept published by	this database nto the corr co-authors to co-authors to populate all fiel Farwell <sup>1</sup> on Managem Co-Authors F s on this abst ed, its publice Elsevier. Cont thors are awith	u may search for any co-au se, you may type them in ect order. This is the orde u be added. If co-author is no complete the co-author is no christine ds to complete the row. ent Group Permission - ract must approve of the pres- tion in an online abstract sup firm below that permission wa are and approve the use of fl	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name - Farwell Farwell entation of this abstract at the SOL plement to the Society's journal, Bit as requested and given for their na heir names on this abstract while	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation • Parthenon Management Group BP Annual Meeting ological Psychiatry, smes to be used in ch. if accepted, will	Please confirm that your co-authors p approved of the presentation and put of this abstract in <i>Biological Psychiat</i> r
search for co Search for co Order Search for co Order Christine Parthenco Attestation ( All co-author and, if accept published by this abstract:	this database nto the corr co-authors to co-authors to populate all fiel Farwell <sup>1</sup> on Managem Co-Authors F is on this abst ed, its publice Elsevier. Cont thors are awitted and public	u may search for any co-au se, you may type them in ect order. This is the orde u be added. If co-author is no complete the row. If its Name • Christine ds to complete the row. ent Group Permission • ract must approve of the press tion in an online abstract supp firm below that permission was are and approve the use of th lished.	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name - Farwell Farwell entation of this abstract at the SOG plement to the Society's journal, Bit as requested and given for their na heir names on this abstract, which	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation • Parthenon Management Group BP Annual Meeting ological Psychiatry, ames to be used in ch, if accepted, will	Please confirm that your co-authors p approved of the presentation and pul of this abstract in <i>Biological Psychiatr</i>
search for co Search for co Order Search for co Order Christine Parthenco Attestation ( All co-authori and, if accept published by this abstract:	this database nto the corr co-authors to co-authors to populate all fiel Farwell <sup>1</sup> on Managem Co-Authors F is on this abstited, its publice Elsevier. Cont thors are awaited and publicors are awaited and publicors are awaited on the second	u may search for any co-au se, you may type them in ect order. This is the orde u be added. If co-author is no u be added. I	thors by using the search box. to the grid below. Please use r that will be printed in our pr ot found, then enter directly in th Last Name - Farwell Farwell Farwell entation of this abstract at the SOG plement to the Society's journal, Bit as requested and given for their na heir names on this abstract, whit e publication of this abstract	If you cannot find a the arrows to move rogram and abstract e table below. Affiliation • Parthenon Management Group BP Annual Meeting ological Psychiatry, ames to be used in ch, if accepted, will	Please confirm that your co-authors approved of the presentation and pu of this abstract in <i>Biological Psychiat</i>

Early Career Investigator Status •

An Early Career Investigator is within ten (10) years of their terminal degree. Are you an early career investigator?

Yes

O No

(13)

#### Video Permission •

ociety of Biological Psychiatry ("SOBP") may make a video recording of your presentation during the The S 2025 SOBP Annual Meeting. In consideration of the decision by the SOBP to include the video recording of your presentation during the 2025 SOBP Annual Meeting in its historical archives, and to make copies of that video recording available for educational purposes only (including posting on the SOBP website), the sufficiency and receipt of such consideration are hereby acknowledged, you agree as follows

1. You grant to SOBP the right to use and portray your name, likeness, voice, personality, personal identification, presentation and participation in the 2025 SOBP Annual Meeting. (All rights are hereinafter referred to as the "Granted Rights.") You agree that the Granted Rights may be used for educational purposes in any manner and by any means, with modifications as SOBP, its successors and assigns, determine in its sole discretion. You acknowledge that you are to receive no payment with respect to any matter referred to herein. Any or all of the Granted Rights shall be freely assignable by SOBP.

2. You agree to release and discharge SOBP, its employees, agents, licensees, successors and assigns from any and all claims, demands or causes of action that you may now have or may hereafter have for libel, defamation, invasion of privacy or right of publicity, infringement of copyright or violation of any other right arising out of or relating to any utilization of the Granted Rights or based upon any failure or omission to make use thereof.

Nature of your participation in the 2025 SOBP Annual Meeting: PRESENTER

O I have read and agree to the above terms and conditions.

confirm that your co-authors preved of the presentation and publication abstract in Biological Psychiatry.

Disclosures



\* You must populate all fields to complete the row.

#### Statement 1 \*

I will not accept payments or reimbursements from an ineligible company (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients) for my role in the planning and delivery of this CME activity. If I am approached by an ineligible company in this regard, I will immediately notify SOBP.

I Agree.

Statement 2 \*

Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public. If I am a presenter, my presentation will meet these standards, and if I'm a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards.

I Agree.

Statement 3 \*

olutoment o

Presentations that promote recommendations, treatment, or manners of practicing medicine that are not within the definition of CME or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients, are prohibited. Presentations devoted to advocacy of unscientific modalities of diagnosis or therapy are prohibited. If I am a presenter, my presentation will meet these standards, and if I'm a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards. Include any ineligible company that you've received funds from.

Be sure to agree to each statement.

#### Statement 4 •

All recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis. If I am a presenter, my presentation will meet these standards, and if I am a planner, I will not approve any content that does not meet these standards. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet these standards.

I Agree

#### Statement 5 •

Presentations must give a balanced view of therapeutic options. Use of generic names will contribute to this impartiality. If the CME educational material or content that includes trade names should include trade names from several companies where available, not just trade names from a single company. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion will meet this standard.

I Agree.

#### Statement 6 \*

Educational materials that are a part of this activity, such as slides, abstracts, and handouts, cannot contain any advertising, trade names, or product-group messages, or ineligible company logos. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion will meet this standard.

I Agree

#### Statement 7 •

The content or format of a CME activity or its related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. If I am a presenter, my presentation will meet this standard, and if I'm a planner, I will not approve any content that does not meet this standard. If I am a session chair and/or an abstract discussant, any contribution I make to the discussion, will meet this standard.

I Agree

#### Statement 8 +

The content of the CME activity must not be influenced by any ineligible company. If I am a presenter, my presentation will meet this standard, and if I am a planner, I will not approve any content that does not meet this standard.

I Agree

#### Statement 9 +

If you are an employee or corporate board member of an ineligible company, we will review your disclosure and decide if further action is, or is not, necessary.

I agree

#### Employee Disclosure •

Are you an employee or owner of an ineligible company, or do you hold stock/equity in a privately held ineligible company?

Yes

O No

#### Disclosure Resolution •

	Yes	No
Is your company/employer/private stock producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients?	۲	0
Is your company/employer/private stock a provider of clinical services directly to patients?	0	۲
Is the content of the activity as a whole related in any way to products or business lines of your company/employer/private stock?	0	۲

14 Resume/CV •

Please upload a copy of your Resume/CV (.DOC/.PDF)



(15) Signature •

I certify that all my affiliations with or financial relationships (e.g., employment, consultancies, honoraria, equity ownership or stock options, grants, contracts, patents, received or pending, or royaltee) with any organization or employ defined as an ineligible company are disclosed complexity here. For purposes of disclosure, financial involvement is defined as any income source having occurred within the last 24 months. In order to accredit the conference, we need to know if your relationship with your ineligible company in relation to the content of your presentation. Please answer these questions if you are employed, an owner or hold stock/equity in a privately held company.

Upload a pdf of your CV

Abstract Submission Fee - Non-Members

If you are not a member or SOBP or your membership dues are not current, you will be required to pay the abstract fee of \$40 USD

Return to Dashboard Submit	Poster	Disclosures 4 Payment 5	
Previous	Save	Submit Abstract and Payment 2	59 of 275 overall words remaining
PAYMENT: The Society of Biological Psych	iatry charges the following fee for ea	ch abstract submitted:	
Members: Presenting authors who are me poster abstract submission fee. If the pres 1, 2022 effective date, the abstract submis	mbers of the Society in good standir enting author has submitted a memb sion fee will need to be paid.	g (membership dues current) effective on or befor ership application prior to September 1, 2022 dead	e October 1, 2022 do not need to pay the oral or line and it has not been approved by the October
Non-Members: \$40.00 US Dollars - This \$ your membership status.	40 fee applies to a non-member who	is the presenting author on an oral or poster abst	tract. Email sobp@sobp.org if you are unsure of
Payment must be submitted with your abs	tract submission. The Society accept	s MasterCard, Visa, and American Express.	
Note: Your abstract is not complete until t must be completed as well	he payment is processed. However,	payment alone does not make your abstract comp	plete. All other steps of the abstract submission
These fees are non-refundable.			
R	eview Order		
Sut	mission Type	Amount	
Pos	iter	40.00 USD	
Tot	al Amount	40.00 USD	
E	nter Credit Card Information lease enter payment information belo	w to complete your order.	
Cred	t Card		
Num	ber+		
Expir		•	
Stree	t yes		
City	Brentwood		
State	TN		
Cour	try United State:	•	
Post	al Code 37129		
Phon	e 61555555	5	
Emai	pmg@test.t	est	

	Subr	nission and Payment Subr	nitted Successfully!	×
Y p	'ou have suo ayment. Yo	ccessfully submitted your F u will soon receive a confir	Poster / Oral Presentation s mation e-mail.	submission and
N	lote: You ma	ay edit the submission unti	I the submission period clo	oses.
Sub				Continue
ulas			Presentation	